Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 188

RaQualia-backed Aratana sets IPO terms

Aratana Therapeutics, a US developer of medicines for pets, sets IPO terms.

Jun 2, 2013

Epizyme raises $77m in flotation

Epizyme sold 5.1 million shares at $15 each compared to plans to offer 4.285 million shares at between $13 and $15 each.

Jun 1, 2013

Epizyme to offer 4.285 million shares

Celgene owns 14.5% of Epizyme ahead of the initial public offering (IPO), after investing the portfolio company's series C round.

May 28, 2013

BioAmber revisits IPO terms

Lanxess-backed converter of feedstocks into chemicals revises IPO terms.

May 16, 2013

Portola sets IPO price range

Biogen Idec-backed Portola Pharmaceuticals set to raise around $103.2m on Nasdaq with $469m market cap

May 14, 2013

Receptos floats on Nasdaq

Receptos raised $73m in its initial public offering (IPO) on the Nasdaq stock exchange.

May 9, 2013

Aratana plans its flotation

In February, Aratana raised $12m in its series C round.

May 5, 2013

FireEye picks four for IPO

The investment banks for the flotation are: Morgan Stanley, Goldman Sachs, JPMorgan Chase and Barclays.

May 5, 2013

Regado looks at Nasdaq

Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.

May 5, 2013

Ambit details IPO plans

Ambit plans to list 4.645 million shares at between $13 and $15 each when it floats on the Nasdaq stock exchange.

May 5, 2013

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here